Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Jeanette K Doorduijn & Hanneke C Kluin-Nelemans. (2013) Management of mantle cell lymphoma in the elderly patient. Clinical Interventions in Aging 8, pages 1229-1236.
Read now
Read now
Simon Rule. (2011) Velcade combinations in mantle cell lymphoma: are we learning anything?. Leukemia & Lymphoma 52:4, pages 545-547.
Read now
Read now
C. Tom Kouroukis, Louis A. V. Fernandez, Michael Crump, Neil Sun Chua, Rena Buckstein, Robert Turner, Sarit Assouline, Richard J. Klasa, Wendy Walsh, Jean Powers & Elizabeth Eisenhauer. (2011) A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172). Leukemia & Lymphoma 52:3, pages 394-399.
Read now
Read now
Oliver Weigert, Michael Unterhalt, Wolfgang Hiddemann & Martin Dreyling. (2009) Mantle cell lymphoma: state-of-the-art management and future perspective. Leukemia & Lymphoma 50:12, pages 1937-1970.
Read now
Read now
Heather E. Eve, David Linch, Wendi Qian, Moira Ross, John F. Seymour, Paul Smith, Lindsey Stevens & Simon A. J. Rule. (2009) Toxicity of fludarabine and cyclophosphamide with or without rituximab as initial therapy for patients with previously untreated mantle cell lymphoma: results of a randomised phase II study. Leukemia & Lymphoma 50:2, pages 211-215.
Read now
Read now
Heather E. Eve, John F. Seymour & Simon A. J. Rule. (2009) Impairment of peripheral blood stem-cell mobilisation in patients with mantle-cell lymphoma following primary treatment with fludarabine and cyclophosphamide±rituximab. Leukemia & Lymphoma 50:3, pages 463-465.
Read now
Read now
Saar Gill & David Ritchie. (2008) Therapeutic options in mantle cell lymphoma. Leukemia & Lymphoma 49:3, pages 398-409.
Read now
Read now
Tadeusz Robak, Ewa Lech-Maranda, Agnieszka Janus, Jerzy Blonski, Agnieszka Wierzbowska & Joanna Gora-Tybor. (2007) Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma. Leukemia & Lymphoma 48:6, pages 1092-1101.
Read now
Read now
Articles from other publishers (16)
Xiao-Xiao Wang, Yan Gao, Jie Jin, Jun-Ning Cao, Ji-Feng Feng, Hua-Qing Wang, Hui-Lai Zhang, Qing-Qing Cai, Zhi-Ming Li, Wen-Qi Jiang & Hui-Qiang Huang. (2021) Bortezomib in combination with fludarabine plus cyclophosphamide for patients with relapsed or refractory mantle-cell lymphoma: results of the LYM-4003 study. Annals of Hematology 100:12, pages 2961-2968.
Crossref
Crossref
Sergio Cortelazzo, Maurilio Ponzoni, Andrés J.M. Ferreri & Martin Dreyling. (2020) Mantle cell lymphoma. Critical Reviews in Oncology/Hematology 153, pages 103038.
Crossref
Crossref
Pamela McKay, Mike Leach, Bob Jackson, Stephen Robinson & Simon Rule. (2018) Guideline for the management of mantle cell lymphoma. British Journal of Haematology 182:1, pages 46-62.
Crossref
Crossref
Johanna C. Kluin-Nelemans & Jeanette K. Doorduijn. (2018) What is the optimal initial management of the older MCL patient?. Best Practice & Research Clinical Haematology 31:1, pages 99-104.
Crossref
Crossref
Sai Ravi Pingali & Timothy S. Fenske. 2017. Hematopoietic Cell Transplants. Hematopoietic Cell Transplants
402
416
.
. 2017. Hematopoietic Cell Transplants. Hematopoietic Cell Transplants
361
444
.
G Hess, U Keller, C W Scholz, M Witzens-Harig, J Atta, C Buske, S Kirschey, C Ruckes, C Medler, C van Oordt, W Klapper, M Theobald & M Dreyling. (2015) Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma. Leukemia 29:8, pages 1695-1701.
Crossref
Crossref
P. McKay, M. Leach, R. Jackson, G. Cook & S. Rule. (2012) Guidelines for the investigation and management of mantle cell lymphoma. British Journal of Haematology 159:4, pages 405-426.
Crossref
Crossref
Sergio Cortelazzo, Maurilio Ponzoni, Andrés J.M. Ferreri & Martin Dreyling. (2012) Mantle cell lymphoma. Critical Reviews in Oncology/Hematology 82:1, pages 78-101.
Crossref
Crossref
Michele Ghielmini & Emanuele Zucca. (2009) How I treat mantle cell lymphoma. Blood 114:8, pages 1469-1476.
Crossref
Crossref
Tadeusz Robak, Anna Korycka, Ewa Lech-Maranda & Pawel Robak. (2009) Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases. Molecules 14:3, pages 1183-1226.
Crossref
Crossref
Huili Wang, Dongmei Wang, Mengqiang Li, Chunxia Zhou, Wenbo Ma, Xiaosan Su, Rongzhi Liu & Shuren Zhang. (2008) Enhanced anti-tumor immunity generated by Rituximab-coated tumor cell vaccine. Cancer Letters 268:1, pages 129-136.
Crossref
Crossref
Mark N. Polizzotto, Constantine S. Tam, Alvin Milner, E. Henry Januszewicz, H. Miles Prince, David Westerman, Max M. Wolf & John F. Seymour. (2006) The influence of increasing age on the deliverability and toxicity of fludarabine‐based combination chemotherapy regimens in patients with indolent lymphoproliferative disorders. Cancer 107:4, pages 773-780.
Crossref
Crossref
Constantine S. Tam, Max Wolf, H. Miles Prince, E. Henry Januszewicz, David Westerman, Katherine I. Lin, Dennis Carney & John F. Seymour. (2006) Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non‐hodgkin lymphoma. Cancer 106:11, pages 2412-2420.
Crossref
Crossref
. (2005) Current Awareness in Hematological Oncology. Hematological Oncology 23:2, pages 82-89.
Crossref
Crossref
Tadeusz Robak. (2005) Rituximab Plus Purine Nucleoside Analogs in the Treatment of Indolent Lymphoid Malignancies. American Journal of Cancer 4:5, pages 279-292.
Crossref
Crossref